Ibsrela was Ardelyx’s largest product and service line in fiscal 2025, bringing in $274.21M of $406.92M (67%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibsrela | $15.60M | — | $158.29M | — | — | $274.21M | |||||
| Xphozah | — | $2.46M | $160.91M | — | — | $103.60M | |||||
| Licensing Revenue | $35.00M | $65.81M | $78.00K | $5.00M | — | $10.09M | |||||
| Licensing | — | — | — | — | — | — | |||||
| Other Cost Of Revenue | — | $41.93M | $14.42M | — | — | — | |||||
| Product Supply | — | — | — | — | — | — | |||||
| Product Sales, Net | $15.60M | — | — | — | — | — | |||||
| Product Supply Revenue | $1.52M | $12.21M | $11.65M | — | — | $15.63M | |||||
| Collaborative Development Revenue | — | — | — | — | — | — | |||||
| Non-Cash Royalty Revenue Related To The Sale Of Future Royalties | — | — | $2.69M | — | $3.40M | $3.40M | |||||
| Other | — | — | — | — | — | — | |||||
| Total | $67.72M | $122.42M | $348.03M | $5.00M | $3.40M | $406.92M |
Ardelyx brought in $406.92M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. Ardelyx regrouped these lines after fiscal 2025, so the total does not compare directly with that year's $3.40M. Ibsrela was the largest at $274.21M (67.4%), ahead of Xphozah at $103.60M (25.5%) and Product Supply Revenue at $15.63M (3.8%). The other two lines brought in $13.49M combined.
Ardelyx began breaking out Xphozah in fiscal 2023 and Non-Cash Royalty Revenue Related To The Sale Of Future Royalties in fiscal 2024. Ardelyx stopped reporting Product Sales, Net ($15.60M in fiscal 2022) and Other Cost Of Revenue ($14.42M in fiscal 2024) as separate lines.
United States was Ardelyx’s largest region in fiscal 2025, bringing in $377.81M of $407.32M (93%).
| Geography | FY 2015 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $15.60M | $83.28M | $319.20M | $377.81M | ||||||
| Japan | — | — | — | — | ||||||
| Europe | — | — | — | — | ||||||
| Asia Pacific | $31.00K | $41.12M | $14.34M | $29.17M | ||||||
| China | — | — | — | — | ||||||
| North America | $36.53M | $59.00K | $78.00K | $342.00K | ||||||
| Hong Kong | — | — | — | — | ||||||
| Total | $52.16M | $124.46M | $333.62M | $407.32M |
Ardelyx brought in $407.32M from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 22.1% from $333.62M in fiscal 2024. United States was the largest at $377.81M (92.8%), ahead of Asia Pacific at $29.17M (7.2%) and North America at $342.00K (0.1%).
Compared with fiscal 2024, Asia Pacific grew 103.4% to $29.17M and United States grew 18.4% to $377.81M. From fiscal 2022 to 2025, combined revenue from these regions grew from $52.16M to $407.32M, a compound annual growth rate of 98.4%. United States' share of the total rose from 29.9% to 92.8%.
Ardelyx (ARDX) reports its revenue by product and service and by geography. In fiscal 2025, Ibsrela was its largest product and service line, bringing in $274.21M (67.4% of the total), followed by Xphozah at $103.60M (25.5%).
Ibsrela was Ardelyx's largest product and service line in fiscal 2025, bringing in $274.21M, or 67.4% of the $406.92M total across its five product and service lines.
United States was Ardelyx's largest region in fiscal 2025, bringing in $377.81M, or 92.8% of the $407.32M total across its three regions.
Asia Pacific grew faster than United States in fiscal 2025, up 103.4% from $14.34M to $29.17M. United States grew 18.4% to $377.81M.
Every figure comes from Ardelyx's annual financial filings, as reported. Each line keeps the name Ardelyx gives it, and years follow its fiscal calendar.
Ardelyx's revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.